We are excited to announce that BenchSci has successfully raised its $63M (US $50M) Series C round, bringing its total investment to $123M. The round was led by Inovia Capital and TCV, with participation from existing investors.
It’s been amazing to watch BenchSci grow from its humble early days as a startup to becoming a huge force for good in the Scientific community. The platform is truly transformative and is leaving a lasting impact on the world. We couldn’t be prouder of Liran and the entire BenchSci team on their growth and traction. The platform is currently used in 16 of the top 20 pharmaceutical companies.
BenchSci’s proprietary ML models are built to understand research experiments like a Ph.D. scientist. They extrapolate scientific data and establish relationships between biological entities. BenchSci empowers close to 50,000 scientists globally to enhance their R&D and clinical outputs.
We believe in the company’s potential to truly revolutionize the drug discovery market and bring lifesaving drugs to market at scale.
Congratulations to the entire BenchSci team on this amazing milestone!
